Efficacy of biologic therapies for biologic-naive Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis.

ABSTRACT:

Background/aims

Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses.

Methods

A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologicnaïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6-12) and maintenance (weeks 30-60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results acros

SUBMITTER: Hibi T 

PROVIDER: S-EPMC7873404 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature